Citations 2
Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).
Denlinger, Crystal S. , Sym, Sun Jin , Bendell, Johanna C. , Kudla, Art, McDonagh, Charlotte F., Czibere, Akos, Chibaudel, Benoist , Yoon, Harry H. , Hecht, J. Randolph, Bang, Yung‐Jue, Maqueda, María , Watkins, David J. , Park, Se Hoon , Arkenau, Hendrik‐Tobias , Bekaii‐Saab, Tanios , Press, Michael F. , Cunningham, David , Bang, Yung‐Jue , Chibaudel, Benoist
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4043-4043
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Vaishampayan, Ulka N. , Matrana, Marc , Zurita, Amado J. , Keam, Bhumsuk , Sundararajan, Srinath , Mowat, Rex B., Dudek, Arkadiusz Z. , Gan, Lu , Vaishampayan, Ulka , McDermott, David F. , Rha, Sun Young , Ho, Thai H. , Lee, Jae‐Lyun , Joseph, Richard W. , Ali, Sarah, Stadler, Walter M. , Haas, Naomi B , Park, Se Hoon , Picus, Joel , Zakharia, Yousef , Atkins, Michael B. , Dudek, Arkadiusz Z
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4510-4510